The difference of BMD between 2019 and 2022 classify by grop of urinary camium levels measured in 2019. by Aroon La-up (14095691)

Subjects:

Non-linear relationship between urinary cadmium and bone mineral density from the adjusted restricted cubic splines model. by Aroon La-up (14095691)

Subjects:

Prevalence of osteoporosis classified by sex, and urinary cadmium level compare between 2019 and 2022. by Aroon La-up (14095691)

Subjects:

Linear Mixed-Effects Model analysis of bone mineral density changes in relation to urinary cadmium levels in a 3-Year Period. by Aroon La-up (14095691)

Subjects:

Data. by Aroon La-up (14095691)

Subjects:

Stratified analysis of the association between urinary cadmium and bone mineral density, by sex. by Aroon La-up (14095691)

Subjects:

Association between baseline urinary cadmium and the three-year change in bone mineral density (ΔBMD). by Aroon La-up (14095691)

Subjects:

Characteristics of the study participants for continuous variables. by Aroon La-up (14095691)

Subjects:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

General characteristics of study subjects. by Soo-Hee Hwang (17767519)

“…COVID-19 did not affect inpatient mortality (p = 0.9608), but in-hospital mortality decreased from 12% to 7% in the medical aid group.</p><p>Conclusion</p><p>Overall, we found that COVID-19 had an impact on admission rates of patients with AMI but did not have a significant impact on in-hospital mortality. …”

HDECO: A method for Decreasing energy and cost by using virtual machine migration by considering hybrid parameters by Arash GhorbanniaDelavar (22563696)

“…</p><p dir="ltr">Compared to the ECIB algorithm and previous approaches, HDECO achieved significant improvements:</p><ul><li><b>Up to 10% reduction in energy consumption</b></li><li><b>8% decrease in overall execution cost</b></li><li><b>Better real execution time and fewer unnecessary migrations</b></li></ul><p dir="ltr">This makes HDECO an effective and lightweight solution for instance-intensive cloud workflows.…”

The SPAM fitted on empirical data. by Kimmo Sorjonen (495847)

The effect of pre-RT D-dimer levels on post-RT changes in D-dimer levels and on survival rates. by Huriye Senay Kiziltan (22298378)

Subjects:

ROC curve according to their D-dimer values in patients with PFS ≥ 1 year and those with PFS < 1 year. p < 0.001 (95% CI: 4-21). by Huriye Senay Kiziltan (22298378)

Subjects: